Harmony Biosciences Holdings, Inc. HRMY R2KR3KPHARMA
Company Overview
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Why Investors Should Care
Generates a return on equity of 20.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 20.4%.
Revenue has grown at a 129.2% CAGR over the past five years.
Trades at a P/E of 11.7, below the sector median of 25.4.
Maintains a net profit margin of 18.9%.
Carries low leverage with a debt-to-equity ratio of 0.16.
Recent Developments
- Dec 2025 Revenue of $868.45M (+21.5% YoY); net profit $158.69M.
- Trailing 12 Months Year-on-year growth — revenue +30.3%, earnings +88.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 129.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 129.17% |
| 1 Year: | 30.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 88.20% |
Stock Price Performance
| 1 Year: | -1.47% |
| 6 Months: | +17.31% |
| 3 Months: | +0.33% |
| 1 Month: | -12.22% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)35.32 · Neutral
P/E of 11.69 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 20.5%.
- Healthy ROCE of 20.4%.
- Compounding revenue at 129.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HRMY Harmony Biosciences Holdings, Inc. R2KR3KPHARMA | 36.13 | 11.69 | $2.10B | 0.00% | 20.45% | 20.46% | 129.17% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 19.84M | 38.01M | 45.61M | 59.67M | 73.82M | 80.73M | 85.31M | 107.03M | 117.21M | 119.13M | 134.22M | 160.27M | 154.62M | 172.81M | 186.04M | 184.73M | 200.49M | 239.46M | 215.39M | 261.28M |
| Gross Profit | - | 16.37M | 31.55M | 37.72M | 49.27M | 61.13M | 66.13M | 70.60M | 88.11M | 94.25M | 98.35M | 109.21M | 127.97M | 127.13M | 140.67M | 143.26M | 152.74M | 162.34M | 179.81M | 170.88M | 198.08M |
| Operating Income | -29.80M | -9.61M | 7.31M | 10.38M | 14.53M | 23.31M | 21.05M | 27.56M | 33.12M | 11.90M | 40.42M | 46.90M | 64.51M | 52.03M | 21.36M | 61.71M | 56.24M | 48.18M | 65.49M | 37.29M | 89.32M |
| Net Income | -31.90M | -38.62M | -27.00K | 1.91M | 7.39M | 14.12M | -9.62M | 21.48M | 23.53M | 87.94M | 29.48M | 34.30M | 38.46M | 38.33M | 11.59M | 46.09M | 45.56M | 39.78M | 50.87M | 32.49M | 75.43M |
| Diluted EPS | -5.26 | -6.30 | -1.34 | -0.14 | 0.13 | 0.24 | -0.17 | 0.35 | 0.39 | 1.44 | 0.48 | 0.56 | 0.63 | 0.67 | 0.20 | 0.79 | 0.78 | 0.68 | 0.87 | 0.55 | 1.28 |
| R&D Expense | 4.34M | 3.43M | 4.17M | 4.23M | 4.68M | 6.50M | 11.74M | 7.58M | 12.67M | 40.55M | 13.29M | 14.97M | 17.50M | 22.19M | 63.58M | 25.39M | 34.54M | 50.16M | 54.96M | 69.38M | 46.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.00M | 159.74M | 305.44M | 437.86M | 582.02M | 714.73M | 868.45M |
| Gross Profit | 4.42M | 132.00M | 249.92M | 354.37M | 460.79M | 557.92M | 670.11M |
| Operating Income | -145.90M | 16.99M | 87.53M | 120.19M | 192.03M | 190.83M | 208.47M |
| Net Income | -151.98M | -36.94M | 34.60M | 181.47M | 128.85M | 145.49M | 158.69M |
| Diluted EPS | -24.07 | -2.48 | 0.58 | 2.97 | 2.13 | 2.51 | 2.71 |
| R&D Expense | 69.59M | 19.45M | 30.37M | 70.89M | 76.06M | 145.82M | 189.59M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 106.70M | 427.07M | - | 673.87M | 811.45M | 999.20M | 1.27B |
| Current Assets | - | - | - | - | 400.29M | 451.07M | 579.25M | 907.01M |
| Cash & Equivalents | - | 24.46M | 228.63M | - | 243.78M | 311.66M | 453.00M | 752.50M |
| Inventory | - | - | - | - | 4.30M | 5.36M | 7.20M | 5.36M |
| Receivables | - | - | - | - | 54.74M | 74.14M | 83.03M | 96.79M |
| Total Liabilities | - | 118.29M | 329.89M | - | 271.03M | 344.46M | 340.05M | 401.41M |
| Current Liabilities | - | 19.89M | 134.54M | - | 78.88M | 163.78M | 175.08M | 252.13M |
| Long Term Debt | - | 97.95M | 194.25M | - | 189.65M | 178.57M | 163.02M | 143.66M |
| Total Debt | - | - | - | - | 191.65M | 193.57M | 179.27M | 163.66M |
| Total Equity | -242.67M | -422.86M | 97.18M | - | 402.84M | 466.99M | 659.15M | 870.22M |
| Shares Outstanding | - | - | - | - | 59.62M | 56.77M | 57.14M | 57.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -75.44M | -2.98M | 98.56M | 144.47M | 219.39M | 219.82M | 348.20M |
| Investing Cash Flow | -127.15M | -2.00M | -100.30M | -141.83M | -46.44M | -67.48M | -39.65M |
| Financing Cash Flow | 143.77M | 209.16M | 7.42M | 6.84M | -105.55M | -11.00M | -9.05M |
| Capital Expenditure | -149.00K | -2.00K | -298.00K | -172.00K | -312.00K | -1.15M | -310.00K |
| Free Cash Flow | -75.58M | -2.99M | 98.26M | 144.29M | 219.07M | 218.67M | 347.89M |
| Share Buybacks | - | 167.00K | - | - | 100.00M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.7% | 82.6% | 81.8% | 80.9% | 79.2% | 78.1% | 77.2% |
| Operating Margin % | -2,433.8% | 10.6% | 28.7% | 27.4% | 33.0% | 26.7% | 24.0% |
| Net Margin % | -2,535.1% | -23.1% | 11.3% | 41.4% | 22.1% | 20.4% | 18.3% |
| ROE % | 35.9% | -38.0% | - | 45.0% | 27.6% | 22.1% | 18.2% |
| ROCE % | -168.1% | 5.8% | - | 20.2% | 29.6% | 23.2% | 20.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.20% | 7.10M | $286.07M |
| 2 | FMR, LLC | 6.14% | 3.57M | $143.97M |
| 3 | Vanguard Portfolio Management LLC | 4.95% | 2.88M | $116.03M |
| 4 | American Century Companies Inc | 4.36% | 2.54M | $102.29M |
| 5 | Dimensional Fund Advisors LP | 4.11% | 2.39M | $96.41M |
| 6 | Vanguard Capital Management LLC | 3.61% | 2.11M | $84.79M |
| 7 | LSV Asset Management | 3.54% | 2.06M | $83.03M |
| 8 | State Street Corporation | 3.19% | 1.86M | $74.89M |
| 9 | Armistice Capital, LLC | 2.69% | 1.56M | $63.00M |
| 10 | Geode Capital Management, LLC | 2.48% | 1.44M | $58.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HRMY
Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTFBtVC1laTZHZ1R3UTNRVERCOENWUE9lV0hhMDNDam9Ia1hCdVI1VmFqWWZPX0pNNjlFZmF5YWhvWkRjNHhNSDZRUTVwNFhBb25GSGc?oc=5" target="_blank">Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, N…
Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE03dWxVd2R0Ym5ZZERkMGxONlFaSVJIR245Tjc1YkFULUZzT29wWGJVbmFLVEFMcEZ0ejF1ZnFHM0N3VUhYUGRYVHlPcm42VXN1Nnc?oc=5" target="_blank">Harmony Biosciences Holdings, Inc. (HRMY) stock price, n…
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It (NASDAQ:HRMY) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxONF83U2JyOHhvVms2dmtpYUFTSHpBZ2ZSSUZqZEl4cFctT2hVQUVjVVBzX0dmV0dzRmJzeW5UWU5oVWt4QmtPWkdKTlE4ZF8zcjBQOUhCM0psU0FKWkF5NmlGTjFseDExOEZhYTBCZTdNUUM2bWpGbFZvNzhaSlBjUUdwWUp2TVdVejZVNU…
HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPV1JZTi1aQTVMRTRzZG5LTTdlS2J0T2o3VWlaUlZmYWhSck00Y0NBUVpwWm54VFZvT2VoVERFY29EVTY1eXJZWFNRVlY1SHJHLVVQU3ozeEhzSGhWSUwzUjNtb3EyRUMyOGlpUm1vbF9mN0FvQm9jbHVoQWk1YWZnUnI4NGpUNHByaFowYm…
HRMY Reiterated by Needham -- Price Target Maintained at $50.00 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPNkVSVU80cVdaMkZlVTZkMWlIOWVUR3g5cTM5enhjYTFjWHk1Zzd6eWNIZ0lzZmVNZTEzM1NCeFJJTGY2NTA3V2xpdHY2U09hRWtCMm03Z3V6QUhnZEFPbUFFZk5Ib0dMcDNqTnFUYXAzVjBkQWJLM1BIdnJEcXhHU0JNVUZ5Q1ZUbEdoQ3…
HRMY or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPT0pNM21qTmdnUEFDM2F2TU01LTZXMjhLTXdsMm9xamhocFprOVZoMVctd2daUmdHWER5Um0tenNLVFRhMFl0emtISFRISGl4aG50UDJ4U2dPRlhwVG1NWkRDc1lKR19xTVYydlV2MnZYREkxbmhVVENuUWlBdVh1UGRBbExYdnowYzBZM1…
HRMY — Frequently Asked Questions
What is the current share price of Harmony Biosciences Holdings, Inc. (HRMY)?
As of 2026-10-23 16:27 PDT, Harmony Biosciences Holdings, Inc. (HRMY) trades at $36.13 on NasdaqGM. Its 52-week range is $25.90 to $42.86.
What is the market capitalisation of HRMY?
Harmony Biosciences Holdings, Inc. (HRMY) has a market capitalisation of $2.10B on NasdaqGM.
What is the P/E ratio of HRMY?
HRMY trades at a trailing price-to-earnings (P/E) ratio of 11.69. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.44.
What is the return on equity (ROE) of HRMY?
HRMY has a return on equity (ROE) of 20.46%. Its return on capital employed (ROCE) is 20.45%.
Is HRMY a good stock to buy?
This page provides a data-driven analysis of Harmony Biosciences Holdings, Inc. (HRMY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.